请选择 进入手机版 | 继续访问电脑版

eNewsTree.com

 找回密码
 立即注册
查看: 590|回复: 0

PFE buy BHVN $11.6 Billion in cash

[复制链接]
发表于 2022-5-10 03:13:34 | 显示全部楼层 |阅读模式
[size=1.385em]NEW YORK & NEW HAVEN, CONN., May 10, 2022--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults.


[size=1.385em]This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510005676/en/
[size=1.385em]Under the terms of the agreement, Pfizer will acquire all outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash. Biohaven common shareholders, including Pfizer, will also receive 0.5 of a share of New Biohaven, a new publicly traded company that will retain Biohaven’s non-CGRP development stage pipeline compounds, per Biohaven common share. The boards of directors of both Biohaven and Pfizer have unanimously approved the transaction. Pfizer will pay transaction consideration totaling approximately $11.6 billion in cash. Pfizer will also make payments at closing to settle Biohaven’s third party debt and for the redemption of all outstanding shares of Biohaven’s redeemable preferred stock. The $148.50 cash consideration represents a premium of approximately 33% to Biohaven’s volume weighted average selling price of $111.70 over the three months prior to the announcement of the transaction.

回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

小黑屋|Archiver|手机版|消息树

GMT-8, 2022-5-28 18:49 , Processed in 0.041754 second(s), 16 queries .

Powered by Discuz! X3.2

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表